Switching to ANGIOMAX

Follow these guidelines for switching patients undergoing percutaneous coronary intervention (PCI) to Angiomax® (bivalirudin):¹

UFH = unfractionated heparin LMWH = low molecular weight heparin

REPLACE-2 Subanalysis: Successful Results in Patients Switched
to ANGIOMAX^2-3

*P = not significant versus prior treatment with UFH or enoxaparin.
^†P<.05 versus prior treatment with UFH or enoxaparin.
CABG = coronary artery bypass graft surgery
TIMI = Thrombolysis in Myocardial Infarction
GP = glycoprotein

• In REPLACE-2, ANGIOMAX was not associated with significant increases in bleeding in patients switched from heparin or enoxaparin in the preceding 48 hours²
• In contrast, patients switched to heparin + GP IIb/IIIa after prior treatment with heparin or enoxaparin (within the preceding 48 hours) experienced increased major/minor bleeding and need for transfusion²

Safety Considerations

ANGIOMAX with provisional use of glycoprotein IIb/IIIa inhibitor is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), and in patients with or at risk for heparin-induced thrombocytopenia and thrombosis syndrome (HIT/HITTS) undergoing PCI. ANGIOMAX is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin. ANGIOMAX is contraindicated in patients with active major bleeding or hypersensitivity to ANGIOMAX or its components. The most common (10%) adverse events for ANGIOMAX were back pain, pain, nausea, headache, and hypotension. An unexplained fall in blood pressure or hematocrit, or any unexplained symptom, should lead to serious consideration of a hemorrhagic event and cessation of ANGIOMAX administration. Please see complete prescribing information.